What is it about?

In a period of two years, willingness to participate in HIV vaccine studies was evaluated among behavioural vulnerable young people. Willingness to participate in future HIV trials was high at the beginning and at the end. Being young and wanting to contribute to the fight against HIV was associated with wanting to participate in experimental vaccine studies.

Featured Image

Why is it important?

Our study reinforces the practicality of conducting HIV vaccine trials in Maputo. It contributed with knowledge that can be leveraged for the development of communication and retention strategies of future HIV vaccine clinical trials to be conducted in Mozambique.


Writing this article has been a remarkable and exhilarating journey. Throughout the process, I have had the privilege of engaging with diverse opinions and accommodating various comments, all while striving to maintain the essence of the story I wished to convey. However, what makes this article truly special to me is the fact that I was fortunate enough to be part of a select group of researchers who had the opportunity to participate in the first HIV vaccine trials in Mozambique. This article represents more than just a personal accomplishment. It is my humble contribution towards the larger goal of discovering a preventive HIV vaccine.

Igor Capitine
Instituto Nacional de Saúde, Moçambique

Read the Original

This page is a summary of: Young at risk-people in Maputo City, Mozambique, present a high willingness to participate in HIV trials: Results from an HIV vaccine preparedness cohort study, PLoS ONE, December 2021, PLOS, DOI: 10.1371/journal.pone.0260126.
You can read the full text:



The following have contributed to this page